SEATTLE — In this Healio Video Perspective from the ARVO meeting, John D. Sheppard, MD, MMSc, FACS, discusses a post hoc analysis investigating Miebo for the treatment of dry eye disease at different levels of severity.
Data for the analysis were collected from the MOJAVE and GOBI trials and included patients treated with Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) who had mild and moderate scores for total corneal fluorescein staining, meibomian gland dysfunction and Schirmer’s test at baseline.
“The post hoc analyses of pulled data from these two phase 3